Esophageal manometry in 28 systemic sclerosis Brazilian patients: Findings and correlations

Diseases of the Esophagus

Volumn 22, Issue 8, 2009, Pages 700-704

  Calderaro, D C ^a   de Carvalho, M A P ^a   Moretzsohn, L D ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Esophageal motility disorder; Manometry; Scleroderma; Systemic

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIGEN; CALCIUM CHANNEL BLOCKING AGENT; CENTROMERE ANTIBODY; NIFEDIPINE; NUCLEAR PROTEIN; SCL 70 ANTIGEN, HUMAN;

ADULT; ARTICLE; BRAZIL; DIFFUSE SCLERODERMA; ESOPHAGUS FUNCTION DISORDER; FEMALE; HUMAN; IMMUNOLOGY; LIMITED SCLERODERMA; MALE; MANOMETRY; MIDDLE AGED; RETROSPECTIVE STUDY; SYSTEMIC SCLEROSIS;

ADULT; ANTIBODIES, ANTINUCLEAR; AUTOANTIGENS; BRAZIL; CALCIUM CHANNEL BLOCKERS; ESOPHAGEAL MOTILITY DISORDERS; FEMALE; HUMANS; MALE; MANOMETRY; MIDDLE AGED; NIFEDIPINE; NUCLEAR PROTEINS; RETROSPECTIVE STUDIES; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED; SCLERODERMA, SYSTEMIC;

EID: 77649282026     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2009.01000.x     Document Type: Article

References (34)

1. Ntoumazios S K, Voulgari P V, Potsis K, Koutis E, Tsifetaki N, Assimakopoulos D A. Esophageal involvement in scleroderma: gastroesophageal reflux, the common problem. Semin Arthritis Rheum 2006; 36 (3): 173-81.
2. Szamosi S, Szekanecz Z, Szücs G. Gastrointestinal manifestations in Hungarian scleroderma patients. Rheumatol Int 2006;26 (12): 1120-4.
3. Marie I, Ducrotte P, Denis P, Hellot M F, Levesque H. Oesophageal mucosal involvement in patients with systemic sclerosis receiving proton pump inhibitor therapy. Aliment Pharmacol Ther 2006; 24: 1593-601.
4. Wipff J, Allanore Y, Soussi F et al. Prevalence of Barrett's esophagus in systemic sclerosis. Arthritis Rheum 2005 52: 2882-8.
5. Domsic R, Fasanella K, Bielefeldt K. Gastrointestinal manifestations of systemic sclerosis. Dig Dis Sci 2008; 53: 1163-74.
6. Clements P J, Becvar R, Drosos A A, Ghattas L, Gabrielli A. Assessment of gastrointestinal involvement. Clin Exp Rheumatol 2003; 21 (Suppl 29): S15-8.
7. Meyer O C, Fertig N, Lucas M, Somogyi N, Medsger T A Jr. Disease subsets, antinuclear antibody profile and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 2007; 34 (1): 104-9.
8. Gonzalez R, Storr M, Bloching H, Seige M, Ott R, Allescher H D. Autoantibody profile in progressive systemic sclerosis as markers for esophageal involvement. J Clin Gastroenterol 2001; 32 (2): 123-7.
9. Stacher G, Merio R, Budka C, Schneider C, Smolen J, Tappeiner G. Cardiovascular autonomic function, autoantibodies, and esophageal motor activity and mixed connective tissue disease. J Rheumatol 2000; 27 (3): 692-7.
10. Bassotti G, Battaglia E, Debernardi V et al. Esophageal dysfunction in scleroderma. Arthritis Rheum 1997; 40 (12): 2252-9.
11. Savas N, Dagli U, Ertugrul E, Kuran S, Sahin B. Autoantibody profile in systemic sclerosis as a marker for esophageal and other organ involvement in Turkish populations. Dig Dis Sci 2007; 52 (11): 3081-6.
12. Dantas R O, Villanova MG, Godoy R A. Esophageal dysfunction in patients with progressive systemic sclerosis and mixed connective tissue diseases. Arq Gastroenterol 1985; 22 (3): 122-6.
13. Henry M A C A, Harbermann M C, Rocha O M. Esophageal motor disturbances in progressive systemic sclerosis. Dis Esophagus 1999; 12: 51-3.
14. Sampaio-Barros P D, Barcelos I K, Carvalho A C O, Samara A M, Marques Neto J F. Acometimento do trato digestivo na esclerose sistêmica. Rev Bras Reumatol 1999; 38 (2): 81-6.
15. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
16. LeRoy E C, Black C, Fleishmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
17. Ragunath K, Williams J G. A review of oesophageal manometry testing in a district general hospital. Postgrad Med J 2002;78(915): 34-6.
18. Spechler S J, Castell D O. Classification of oesophageal motility abnormalities. Gut 2001; 49 (1): 145-51.
19. Alonso O, Hernandez D, Moreno E et al. The real value of lower esophageal sphincter measurement for predicting acid gastroesophageal reflux or Barrett's esophagus. J Gastrointest Surg 2005; 9 (7): 973-9.
20. Richter J E, Wu WC, Johns D N et al. Esophageal manometry in 95 healthy adult volunteers: variability of pressure with age and frequency of abnormal contractions. Dig Dis Sci 1987; 32 (6): 583-92.
21. Lock G, Holstege A, Lang B, Scholmerich J. Gastrointestinal manifestations of progressive systemic sclerosis. Am J Gastroeterol 1997; 92 (5): 763-71.
22. Sjögren R W. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994; 37 (9): 1265-82.
23. Sallam H, Macnearney T A, Chen J D Z. Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther 2006; 23 (6): 691-712.
24. Kaye S A, Denton C P. Gastrointestinal manifestations of systemic sclerosis (scleroderma). In: Basow D S (ed). UpTo-Date. Waltham, MA: UpToDate, 2008.
25. Park RHR, McKillop J H, Belch J J, Faichney A, MacKenzie J F. Achalasia-like syndrome in systemic sclerosis. Br J Surg 1990; 77 (1): 46-9.
26. Dantas R O, Lôbo C J, Ferriolli E, Matsuda N M. Influência da idade na pressão do esfíncter inferior do esôfago. Arq Gastroenterol 1992; 29 (2): 39-42.
27. Airò P, Della Casa D, Danieli E, Missale G, Cattaneo R, Cestari R. Oesophageal manometry in early and definite systemic sclerosis. Clin Rheumatol 2005; 24 (4): 370-6.
28. Andrews J M, Heddle R, Hebbard G S, Checklin H, Besanko L, Fraser R J. Age and gender affect likely manometric diagnosis: audit of a tertiary referral hospital clinical esophageal manometry service. J Gastroenterol Hepatol 2009; 24 (1): 125-8.
29. Andrade L E C, Leser P G. Auto-anticorpos na esclerose sistêmica. Rev Bras Reumatol 2004; 44 (3): 215-23.
30. Leroy E C et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15 (2): 202-5.
31. Kinuya K, Nakajima K, Kinuya S, Michigishi T, Tonami N, Takehara K. Esophageal hypomotility in systemic sclerosis: close relationship with pulmonary involvement. Ann Nucl Med 2001; 15 (2): 97-101.
32. Smythe A, Troy G P, Ackroyd R, Bird N C. Proton pump inhibitor influence on reflux in Barrett's oesophagus. Eur J Gastroenterol Hepatol 2008; 20 (9): 881-7.
33. Spengler M I, Leroux M B, Svetaz M J, Contesti J F, Parente F M, Bertoluzzo S M. Nifedipine effect on red cell rheological properties in patients with systemic scleroderma. Clin Hemorheol Microcirc 2007; 36 (2): 105-10.
34. Bassotti G, Annese V. Review article: pharmacological options in achalasia. Aliment Pharmacol Ther 1999; 13 (11): 1391-6.